Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,159 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Adhesive Dental
Interventions: Tetranite; Device
Lead sponsor: RevBio; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: pharmacological study, dual x-ray absorptimetry; Other · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 51 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Dental Caries
Interventions: 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 10 Years to 14 Years
Enrollment: 2,025 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more

Conditions: Geographic Atrophy
Interventions: JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more

Conditions: Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Interventions: NAV4694; Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 80 Years
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 48 more

Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions: IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX; Drug
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Austin, Texas • Irving, Texas • San Antonio, Texas

Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions: Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 60 Years
Enrollment: 1,875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 404
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more

Conditions: Chronic Renal Failure Requiring Hemodialysis
Interventions: Epoetin Hospira; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 115
States / cities: Azusa, California • Bakersfield, California • Bellflower, California + 50 more

Conditions: Actinic Keratoses
Interventions: imiquimod cream, 3.75%, Vehicle Cream; Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more

Conditions: Central Retinal Vein Occlusion
Interventions: aflibercept, bevacizumab; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more

Conditions: Peripheral Artery Disease, Atherosclerosis, Artery Diseases, Peripheral, Plaque, Atherosclerotic, Occlusive Arterial Disease
Interventions: RANGER™ Paclitaxel Coated Balloon, Paclitaxel, Standard Balloon Angioplasty; Device · Drug · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 20 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 42
States / cities: Fairhope, Alabama • Aurora, Colorado • Stratford, Connecticut + 38 more

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Vamorolone; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: PTSD
Interventions: Accelerated, Multi-Couple Group CBCT for PTSD; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Killeen, Texas

Conditions: Sarcoma
Interventions: dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 209
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 11
States / cities: Irvine, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Solid Tumor
Interventions: MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Traumatic Brain Injury
Interventions: Autologous HB-adMSCs, Normal Saline; Biological · Drug
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Interventions: VERU-111, Enzalutamide, Abiraterone; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 40
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more

Conditions: Bipolar Disorder
Interventions: lithium, valproate, bupropion, paroxetine, lamotrigine, risperidone, inositol, tranylcypromine, Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythms Therapy; Drug · Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 15 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 11
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 8 more

Conditions: Premature Ejaculation
Interventions: IX-01 400 mg, Placebo, IX-01 800 mg, IX-01 1200 mg; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 29
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 25 more

Search by objective public record fields.

Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Alzheimer's Plasma Extension

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Clinical Procedures to Support Research in ALS

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)